Similarly, in the X-linked blood coagulation disorder hemophilia A, large mutations in the F8 gene and lack of central tolerance can result in the mounting of inhibitory anti-drug antibody (ADA) responses to the recombinant FVIII protein, which is administered as replacement therapy (5). This evidence concerns the gene ADA and hemophilia A.